

NovaSterilis, Inc. Awarded \$672,000 NIH Phase II Small Business Grant for Tendon Sterilization

ITHACA, NY, September 8, 2007 – **NovaSterilis Inc.** has been awarded a Phase-II Small Business Innovation Research (SBIR) grant in the amount of \$755,500 from the U.S. National Institutes of Health for its project entitled “Terminal Sterilization of Tendon Allografts Using Supercritical CO₂.” The funding will be used to optimize the sterilization of soft tissue allografts in terminal packaging using supercritical CO₂.

Current methods used for tendon and other musculoskeletal tissue sterilization are imperfect, and often erode the osteogenic and biomechanical properties of the allograft. At **NovaSterilis**, sterilization of such tissue is achieved without compromising the integrity of transplanted tendon, skin, and bone. The SBIR grant will allow the company to conduct complete biomechanical analysis of soft tissue allografts post full cycle terminal sterilization, as well as explore and validate various packaging alternatives that facilitate the transport, shipment and use of allograft tissue in transplant centers.

“This SBIR funding will help **NovaSterilis** validate and broaden its technology platform so we can continue to provide the tissue bank industry with an expanding product line of allograft products that exhibit the highest levels of safety for recipients,” said **David C. Burns, President and CEO of NovaSterilis**.

About NovaSterilis: NovaSterilis, Inc., which developed the NOVA 2200™, is a privately held biotechnology company located in Ithaca, NY. NovaSterilis develops and commercializes proprietary supercritical carbon dioxide-based products and technologies for the sterilization of biomedical materials, thereby addressing challenging issues facing the tissue and life-sciences industries. For more information about NovaSterilis or the NOVA 2200™, please visit the Company’s website at www.novasterilis.com.